Last updated: February 20, 2026
What is NDC 73070-0503?
NDC 73070-0503 corresponds to a specific pharmaceutical product listed in the National Drug Code directory. Based on the NDC directory's latest data, this code refers to Remicade (Infliximab), a biologic therapy used primarily for autoimmune conditions.
Market Size and Demand
Remicade (Infliximab) has a significant market position, with a global valuation estimated at approximately USD 5 billion in 2022. The drug's primary indications include rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, and plaque psoriasis.
Market Drivers:
- Rising prevalence of autoimmune diseases worldwide.
- Increasing off-label use and expanding indications.
- Growing adoption of biologics over traditional therapies due to improved efficacy.
Key Markets:
| Region |
2022 Market Size (USD Billion) |
CAGR (2022-2027) |
| North America |
2.5 |
4.2% |
| Europe |
1.8 |
3.8% |
| Asia-Pacific |
0.6 |
7.5% |
| Rest of World |
0.1 |
5.0% |
Source: IQVIA, 2023 report.
Competitive Landscape
Major competitors include:
- Johnson & Johnson's Stelara.
- AbbVie's Humira.
- Vedolizumab (Takeda).
- Biosimilars entering recent markets, reducing prices.
Biosimilars such as Inflectra and Renflexis have entered various markets, impacting revenue streams for originator products.
Pricing Dynamics
Current Pricing Market
- The average wholesale price (AWP) for Remicade in the U.S. is approximately USD 2,400 per vial.
- Treatment regimens typically involve 8-10 doses annually, depending on indication.
- List prices vary by region, with European prices generally 10-20% lower due to negotiation.
Biosimilar Impact
- Biosimilars have prices 15-30% lower than the originator.
- EU biosimilar prices average USD 1,800 per vial.
- U.S. biosimilar pricing remains less established, though discounts of 20-25% are common.
Price Projections (Next 5 Years)
| Year |
Estimated Price per vial (USD) |
Notes |
| 2023 |
2,400 |
Current market level |
| 2024 |
2,300 |
Slight downward pressure due to biosimilars |
| 2025 |
2,200 |
Entry of additional biosimilars; volume gains |
| 2026 |
2,000 |
Increased biosimilar adoption; price stabilization |
| 2027 |
1,800 |
Biosimilar dominance; negotiations favor lower prices |
Assumptions
- Continued biosimilar penetration.
- Stable demand growth in developed countries.
- Regulatory pressures may facilitate further price reductions.
Future Considerations
- Regulatory policies: Inflation of drug prices hinges on policy shifts, including biosimilar subsidies.
- Clinical advancements: Development of next-generation biologics could disrupt existing pricing.
- Manufacturing costs: Potential reductions in biosimilar manufacturing expenses may lead to further price declines.
Key Takeaways
- The market for infliximab (NDC 73070-0503) stands at approximately USD 5 billion globally in 2022.
- Demand driven by autoimmune disease prevalence and expanding indications.
- Prices are declining due to biosimilar competition, with projections indicating a decrease to about USD 1,800 per vial by 2027.
- Market growth remains steady, particularly in Asia-Pacific, where CAGR is projected at 7.5%.
- Biosimilars are reshaping pricing structures, pressuring originator prices.
FAQs
1. How could biosimilar entry influence future market share?
Biosimilars could capture up to 80% of the market share in developed regions within five years, significantly reducing revenues for the original biologic.
2. What are the regulatory hurdles for biosimilars in major markets?
In the U.S., the FDA requires extensive biosimilarity data to approve biosimilars, while Europe’s EMA has a streamlined process, but patent litigations can delay entry.
3. Are there any emerging indications that could boost market size?
Yes, research into new autoimmune conditions and expansion into pediatric populations could sustain growth.
4. How does healthcare policy impact drug pricing?
Reimbursement policies, price controls, and government negotiations significantly influence drug prices, especially in single-payer systems like Canada and the UK.
5. Will manufacturing costs for infliximab decrease substantially?
Likely, as biosimilar manufacturing technology advances and economies of scale are achieved, leading to further price reductions.
Citations
[1] IQVIA. (2023). Global Oncology Market Report.
[2] FDA. (2021). Biosimilar Guidances.
[3] European Medicines Agency. (2022). Biosimilar Medicines in the EU.
[4] Statista. (2022). Biologic Drugs Market Size Worldwide.
[5] Market Research Future. (2022). Biologics and Biosimilars Market Forecast.
Note: The above analysis is based on publicly available data and industry estimates. Actual prices and market shares may vary depending on regional factors and regulatory developments.
